Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.59 |
| ▸ | ACE | P12821 | 3/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.41 |
| ▸ | GRN | P28799 | 2/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655470 | 1.00 | ACE2 (0.59) | ACE2ACECYP11B1CYP11B2GRN | |
| SCHEMBL7384406 | 0.94 | ACE2 (0.54) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL1656651 | 0.91 | CYP11B1 (0.52) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL3681437 | 0.91 | ACE2 (0.48) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL7531327 | 0.90 | ACE2 (0.52) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL7382789 | 0.89 | ACE2 (0.46) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL7424859 | 0.88 | ACE2 (0.51) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL7422079 | 0.88 | ACE2 (0.45) | ACE2ACECYP11B1CYP11B2 | |
| SCHEMBL7391521 | 0.88 | ACE2 (0.45) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL1655465 | 0.87 | ACE2 (0.45) | ACE2ACECYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011513491-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2262491-A1 | THERAPY FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT | Ore Pharmaceuticals Inc. (US) | 2010-12-22 | — | — | EP | claimed |
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | claimed |
| WO-2009114516-A1 | THERAPY FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT | ORE PHARMACEUTICALS INC. (US) | 2009-09-17 | — | — | WO | claimed |
| WO-2021202399-A1 | METHODS OF TREATING CORONAVIRUS INFECTIONS USING ANGIOTENSIN-CONVERTING ENZYME 2 INHIBITORS | KUMUDA, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3717077-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
| US-8759295-B2 | Peptide-peptidase inhibitor conjugates and methods of using same | AMYLIN PHARMACEUTICALS, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20100292172-A1 | Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292172-A1 | Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same | DNPEP, PEPD, VIP | ACE2 91/4885ACE 24/4885CYP11B1 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.